Disease progression model of 4T1 metastatic breast cancer

Yang, Liang; Ling, Yong; Zhu, Xiao; Yu, Feng; Fu, Yu; Kong, Daming; Lu, Wei; Zhou, Tianyan

doi:10.1007/s10928-020-09673-5

Cited by 32 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mice on CR (pre-or post-4T1 implantation), but not on FMD or LCC, also had less visible large pulmonary metastases (>1.5 mm in size) (Fig. 3c), which are indicative of more advanced metastatic growth 20,26 . Only the daily CR (pre-and post-4T1 implantation) groups exhibited a significant reduction in metastatic lesions in H&Estained lung sections (Fig.…”

Section: Resultsmentioning

confidence: 98%

Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition

et al. 2021

View full text Add to dashboard Cite

Cancer incidence increases with age and is a leading cause of death. Caloric restriction (CR) confers benefits on health and survival and delays cancer. However, due to CR’s stringency, dietary alternatives offering the same cancer protection have become increasingly attractive. Short cycles of a plant-based diet designed to mimic fasting (FMD) are protective against tumorigenesis without the chronic restriction of calories. Yet, it is unclear whether the fasting time, level of dietary restriction, or nutrient composition is the primary driver behind cancer protection. Using a breast cancer model in mice, we compare the potency of daily CR to that of periodic caloric cycling on FMD or an isocaloric standard laboratory chow against primary tumor growth and metastatic burden. Here, we report that daily CR provides greater protection against tumor growth and metastasis to the lung, which may be in part due to the unique immune signature observed with daily CR.

show abstract

Section: Resultsmentioning

confidence: 98%

Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The tumor growth inhibition (TGI) model [ 10 ] constitutes a highly valuable preclinical methodology in oncology for the selection of therapeutic candidates and the design of optimal clinical evaluation strategies for the in vivo evaluation of anti-tumor effect [ 11 , 12 , 13 , 14 , 15 , 16 ]. The Simeoni TGI model has been widely implemented to characterize the pharmacological response of drug candidates in single-agent and combination experiments by linking drug concentration in the target tissue to the inhibition of tumor growth [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice

et al. 2020

View full text Add to dashboard Cite

MBQ-167 is a dual inhibitor of the Rho GTPases Rac and Cdc42 that has shown promising results as an anti-cancer therapeutic at the preclinical stage. This drug has been tested in vitro and in vivo in metastatic breast cancer mouse models. The aim of this study is to develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK-PD) model of MBQ-167 to predict tumor growth inhibition following intraperitoneal (IP) administration in mice bearing Triple Negative and HER2+ mammary tumors. PBPK and Simeoni tumor growth inhibition (TGI) models were developed using the Simcyp V19 Animal Simulator. Our developed PBPK framework adequately describes the time course of MBQ-167 in each of the mouse tissues (e.g., lungs, heart, liver, kidneys, spleen, plasma) and tumor, since the predicted results were consistent with the experimental data. The developed PBPK-PD model successfully predicts tumor shrinkage in HER2+ and triple-negative breast tumors after the intraperitoneal administration of 1 and 10 mg/kg body weight (BW) dose level of MBQ-167 three times a week. The findings from this study suggest that MBQ-167 has a higher net effect and potency inhibiting Triple Negative mammary tumor growth compared to HER2+ and that liver metabolism is the major route of elimination of this drug.

show abstract

“…Above data suggested that CM-cancer possessed enormous potential on personalized immunotherapeutics. 4T1 tumor have strong spontaneous metastatic capability 41 . In the therapy group with CM-4T1 in Balb/c mice with 4T1 tumor, the lung metastases of 4T1 tumors were significantly inhibited in contrast with the control groups of P1-P4, as shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Cancer Immunotherapy Based on Carbon-Quantum-Dots

Liang¹,

Lei²,

Tao³

et al. 2021

Preprint

View full text Add to dashboard Cite

Cancer immunotherapy based on carbon-quantum-dots (CQDs) has proven effective. The CQDs composited cancer cell (CM-cancer) exhibit robust customized immunogenicity, which can recruit macrophages and dendritic cells to effectively deliver the cancer antigens into lymph nodes to activate CD8+ T cells, and eventually leads to an anti-cancer immune response all over the body. The CM-cancer is not only able to inhibit primary tumors, but also clearly eliminate metastatic tumors. Our research demonstrates a promising personalized cancer immunotheraputic technology for potential clinical applications.

show abstract

Disease progression model of 4T1 metastatic breast cancer

Cited by 32 publications

References 34 publications

Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition

Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition

Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice

Cancer Immunotherapy Based on Carbon-Quantum-Dots

Contact Info

Product

Resources

About